Navigation Links
The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use
Date:11/3/2008

Majority of Physicians are Most Concerned About Lack of Reimbursement for Vascular Catheter-Associated Infections, According to a New Report from

Decision Resources

WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the Medicare Hospital-Acquired Conditions Initiative will have a significant impact on antibiotic prescribing and infection control practices for hospital-acquired infections. The new Physician & Payer Forum report Hospital Anti-Infectives: Insights on the Impact of Medicare Reforms, Formulary Inclusion, and Uptake of Novel Antibiotics and Antifungals finds that approximately one-third of surveyed physicians expect to increase their use of antibiotic prophylaxis to help prevent the development of hospital-acquired infections.

According to the report, surveyed physicians are highly concerned about Medicare's decision to reduce reimbursement of the costs of treating certain hospital-acquired infections. Following the implementation of the new initiative in the United States on October 1, 2008, Medicare will no longer cover the additional costs of treating ten conditions acquired during a hospital stay, including vascular catheter-associated infections, catheter-associated urinary tract infections and surgical site infections following certain elective procedures. The report finds that 62 percent of infectious disease specialists and 73 percent of critical care specialists are most concerned about Medicare's decision to no longer reimburse the cost of treating vascular catheter-associated infections.

"Physicians we surveyed are concerned about the lack of Medicare reimbursement for vascular catheter-associated infections," said Danielle Drayton, Ph.D., director at Decision Resources. "Many physicians indicate these changes will prompt them to increase their prescribing of carbapenems and anti-MRSA therapies, most notably Cubist's Cubicin and Pfizer's Zyvox."

The report finds that, in the wake the Medicare HAC Initiative, infectious disease and critical specialists expect to rely more heavily on antibiotics in some form (e.g., prophylaxis, empiric use) to prevent and manage the treatment of hospital acquired infections. Pharmacy and Therapeutic Committee members, however, expect greater emphasis on antibiotic oversight and cost-effectiveness.

Hospital Anti-Infectives: Insights on the Impact of Medicare Reforms, Formulary Inclusion, and Uptake of Novel Antibiotics and Antifungals is based on a U.S. survey of 50 infectious disease specialists, 51 critical care specialists, and 22 infectious disease specialists who are also Pharmacy and Therapeutic Committee members of their hospital. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.

Christopher Comfort Elizabeth Marshall

781-296-2597 781-296-2563

ccomfort@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
4. Medicare Coverage Recommended for In-Home Sleep Testing
5. MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress
6. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
7. Medicare Approves in Home Sleep Apnea Testing
8. Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case
9. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
10. Arcadian Health Plan Addresses Medicare Doctor Payment Cuts
11. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):